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Background. The aims of the study were to determine the prevalence of cardiometabolic risk factors and establish the
proportion of people with psychosis meeting criteria for the metabolic syndrome (MetS). The study also aimed to identify
the key lifestyle behaviours associated with increased risk of the MetS and to investigate whether the MetS is associated
with illness severity and degree of functional impairment.
Method. Baseline data were collected as part of a large randomized controlled trial (IMPaCT RCT). The study took place
within community mental health teams in ﬁve Mental Health NHS Trusts in urban and rural locations across England. A
total of 450 randomly selected out-patients, aged 18–65 years, with an established psychotic illness were recruited. We
ascertained the prevalence rates of cardiometabolic risk factors, illness severity and functional impairment and calculated
rates of the MetS, using International Diabetes Federation (IDF) and National Cholesterol Education Program Third
Adult Treatment Panel criteria.
Results. High rates of cardiometabolic risk factors were found. Nearly all women and most men had waist circumfer-
ence exceeding the IDF threshold for central obesity. Half the sample was obese (body mass index≥ 30 kg/m2) and a ﬁfth
met the criteria for type 2 diabetes mellitus. Females were more likely to be obese than males (61% v. 42%, p < 0.001). Of
the 308 patients with complete laboratory measures, 57% (n = 175) met the IDF criteria for the MetS.
Conclusions. In the UK, the prevalence of cardiometabolic risk factors in individuals with psychotic illnesses is much higher
than that observed in national general population studies as well as in most international studies of patients with psychosis.
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Introduction
The diagnosis of a psychotic illness such as schizo-
phrenia or bipolar disorder is associated with a reduced
life expectancy of 15–25 years, mostly due to increased
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cardiovascular deaths (Saha et al. 2007; Kilbourne et al.
2009; Brown et al. 2010; Chang et al. 2011). A recent
meta-analysis has demonstrated that the pooled relative
risk of mortality among those with psychoses is 2.54
(2.35–2.75) times that of the general population, and
higher rates of mortality for those with psychoses
when compared with depressive and anxiety disorders
(Walker et al. 2015). Cardiometabolic risk factors are
common in psychosis (McEvoy et al. 2005; Leucht et al.
2007; Osborn et al. 2007; De Hert et al. 2009; Kilbourne
et al. 2009). A recent meta-analysis of international stu-
dies reported prevalence rates of 44% for central obesity,
19.5% for hyperglycaemia, 10.9% for diabetes, 39% for
hypertension and 39% for dyslipidaemias, with rates in-
creasing with age (Mitchell et al. 2013).
Clustering of cardiometabolic risk factors is termed
the metabolic syndrome (MetS) (Alberti et al. 2005).
Individuals with the MetS have a 3- to 6-fold increased
risk of developing type 2 diabetes mellitus (Hanley
et al. 2005; De Hert et al. 2011) and a 2- to 6-fold risk
of mortality due to cardiovascular disease (CVD)
(Hanley et al. 2005). On meta-analysis, a third of
patients with schizophrenia have the MetS, with
this proportion increasing with duration of illness
(Mitchell et al. 2013). Slightly higher MetS rates of
34% are seen in multi-episode patients (Vancampfort
et al. 2013b) while the deﬁcit syndrome (i.e. negative
symptoms of psychosis that are present as enduring
traits) in schizophrenia is in itself associated with
higher CVD risk (Arango et al. 2011). Similar rates of
the MetS have been observed in bipolar disorder
(37%) (Vancampfort et al. 2013a) and schizo-affective
disorder (27–42%) (Basu et al. 2004; Bobes et al. 2012),
although recently the Second Australian National
Survey of Psychosis reported higher rates of 61% in
those with psychotic disorders, suggesting an increas-
ing prevalence with time (Morgan et al. 2014). It is
possible to prevent the emergence of CVD risk in psy-
chosis with the use of psychosocial interventions in the
short term, though this is not sustained once the inter-
vention is discontinued (Alvarez-Jimenez et al. 2010).
Strategies do exist to manage established cardiometa-
bolic risk factors (Lester et al. 2014), but despite this,
a recent UK national audit reported screening rates
for metabolic side effects of antipsychotic medication
of only 11% (Barnes et al. 2007). This is further com-
pounded by the low treatment rates of identiﬁed cardio-
metabolic risk factors in psychosis (Nasrallah et al. 2006).
The recent Schizophrenia Commission Report (UK) high-
lighted the disparity of care for individuals with psy-
chosis and emphasized the need for improved physical
health intervention (Schizophrenia Commission, 2012).
Encouragingly, various UK medical Royal colleges
have recently agreed joint management strategies for
CVD risk in psychotic illnesses (Lester et al. 2014).
In this study we aimed:
(1) To determine the prevalence of cardiometabolic
risks factors and establish the proportion of people
with psychosis meeting the International Diabetes
Federation (IDF) criteria for the MetS.
(2) To identify the key lifestyle behaviours associated
with increased risk of the MetS.
(3) To investigate whether the presence of the MetS is
associated with illness severity and degree of func-
tional impairment.
Method
Study design
This study used baseline data from 450 randomly
selected patients with established (multi-episode) psy-
chosis recruited as part of the National Institute for
Health Research-funded study: Improving Physical
Health and Reducing Substance Use in Severe Mental
Illness; a randomized controlled trial (IMPaCT RCT)
(Gaughran et al. 2013).
Setting
The study took place in community mental health
teams (CMHTs) in ﬁve Mental Health NHS Trusts,
covering urban (Lambeth, Southwark, Lewisham,
Croydon, Greenwich, Bexley, Bromley) and rural
(Staffordshire, Somerset and Sussex) boroughs across
England (Gaughran et al. 2013).
Subjects
Potential participants were identiﬁed through their
care-coordinator. All care-coordinators in participating
CMHTs were approached in a random sequence and
invited to participate. Patients on each participating
care coordinator’s caseload, meeting the inclusion cri-
teria, were likewise approached in a random order.
These patients were entered into a random numbers
generator to create a randomly ordered list from
which to approach potential participants. Researchers
then approached these patients sequentially to partici-
pate in the RCT. In situations where a patient did not
wish to take part in the study or was uncontactable,
the researcher selected another patient from the list in
that random order.
The inclusion criteria were as follows: aged between
18 and 65 years old; a primary diagnosis of a psychotic
illness [International Classiﬁcation of Diseases
(ICD)-10 diagnosis: F20–29, including schizophrenia,
schizo-affective disorder, bipolar affective disorder
(BPAD) and delusional disorder, F31.2, F32.3 and
F33.3]. The exclusion criteria included: a primary
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diagnosis of intellectual disability (as deﬁned by
ICD-10 codes F70–F79 for intellectual disabilities); a
ﬁrst episode of psychosis (FEP); a primary substance
misuse disorder (excluding cigarettes); a serious physi-
cal illness that could independently have an impact on
metabolic measures; pregnant or up to 6 months post-
partum; and receiving intensive input for a medical or
terminal condition. Of patients screened, 39% (1043/
2663) met the inclusion criteria, with the majority
excluded for not meeting the diagnostic inclusion cri-
terion (though the exact percentage excluded by each
exclusion criterion is not known).
Clinical and sociodemographic variables
Sociodemographic and clinical data including gender,
age, ethnicity, diagnosis and self-reported duration of
illness were collected. Diagnoses were based on
ICD-10 diagnostic criteria and were extracted from
the documented diagnosis in the clinical notes at the
time of recruitment. Participants’ mental health status
was measured using the Positive And Negative
Syndrome Scale (PANSS; Kay et al. 1989), the Global
Assessment of Functioning (GAF; American Psychiatric
Association, 2002) and the Montgomery–Åsberg
Depression Rating Scale (MADRS; Montgomery &
Åsberg, 1979). Current alcohol, smoking and cannabis
use was recorded using the following measures:
the Alcohol Use Disorders Identiﬁcation Test (AUDIT;
Saunders et al. 1993); the Nicotine Dependence
Questionnaire (Fagerstrom, 1978; Fagerstrom &
Schneider, 1989); Timeline Follow-Back (Sobell &
Sobell, 1992); and a urine drug screen. Total scores
were derived from individual scale items. If any individ-
ual items were missing, then the total score was treated
as missing. Data for all measures were collected through
face-to-face interviews conducted by trained research
assistants.
Cardiometabolic risk factors
Height, weight and blood pressure (BP) were mea-
sured using standardized techniques. The BP values
presented are the second BP measurements, taken
after an interval of 5 min. Waist circumference was
measured at the umbilicus with the patient standing.
As both serum glucose and triglycerides are affected
by recent food ingestion, we took fasting blood
samples.
Obesity was deﬁned using the World Health
Organization reference standard [body mass index
(BMI)≥ 30 kg/m2]. Diabetes was diagnosed based on
measured glycated haemoglobin (HbA1c) of ≥48
mmol/mol (≥6.5%) or fasting glucose ≥7.0 mmol/l or
a prior diagnosis of diabetes. In addition, in keeping
with recent guidance, an HbA1c of 42–46 mmol/mol
(6–6.4%) was taken to indicate glucose dysregulation
or a high risk of diabetes.
The IDF deﬁnitions of other cardiometabolic risk fac-
tors and of the MetS were used (see Table 1) (Alberti
et al. 2005, 2006). However, we extended the deﬁnition
of the MetS to include an HbA1c value ≥42 mmol/mol
(≥6%), as this is consistent with a raised fasting
plasma glucose ≥5.6 mmol/l (The International Expert
Committee, 2009; Lester et al. 2014).
Additionally, we also determined if each patient met
the adapted National Cholesterol Education Program
(NCEP) Third Adult Treatment Panel (ATP-III) criteria
(NCEP ATP-III criteria) (Grundy et al. 2005), to allow
for comparison with selected studies. The ATP-III clas-
siﬁcation requires three of ﬁve criteria to be met for a
diagnosis of the MetS and an abnormal waist circum-
ference is not obligatory. In comparison with the IDF
MetS criteria, the ATP-III criteria have a higher thresh-
old for abnormal waist circumference, with 102 cm for
males and 88 cm for females being the cut-offs. The
other four criteria are comparable with the IDF criteria.
Table 1. Diagnostic criteria for the metabolic syndrome (International Diabetes Federation criteria) (Alberti et al. 2006)
Diagnostic criteria
Central obesity
Men Waist circumference ≥94 cm in Europid men, ≥90 cm in South Asian men
Women Waist circumference ≥80 cm in Europid women, ≥80 cm in South Asian
women
Plus any two of the following: raised
triglycerides
≥1.7 mmol/l or speciﬁc treatment for this lipid abnormality
High-density lipoprotein-cholesterol
Men <1.03 mmol/l
Women <1.29 mmol/l or speciﬁc treatment for this lipid abnormality
Raised blood pressure Systolic blood pressure≥130 mmHg or diastolic blood pressure≥85 mmHg
or treatment of previously diagnosed hypertension
Raised fasting plasma glucose ≥5.6 mmol/l or previously diagnosed type 2 diabetes
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Hypertension was deﬁned on the basis of a mea-
sured BP of either a systolic measure of 130 mmHg
and/or a diastolic measure of 85 mmHg or existing
treatment with antihypertensive medication.
The Dietary Instrument for Nutrition Education
(DINE; Roe et al. 1994) was used to assess the dietary
patterns of participants over the past week.
Respondents were classiﬁed according to their satu-
rated fat, unsaturated fat and ﬁbre intake, based on
self-reported consumption of various foods. The
International Physical Activity Questionnaire was
used to measure the intensity of physical activity
(high, moderate, low) and the duration of physical ac-
tivities over the previous week (Craig et al. 2003).
Statistical analysis
Statistical analyses were performed using the IBM
Statistical Package for Social Sciences Statistics for
Windows, version 20.0 (USA). Descriptive measures
were used for the basic demographic and clinical vari-
ables as well as for variables relating to the evaluation
of metabolic dysregulation. Student’s t test for para-
metric data and the χ2 test for categorical variables
were employed. All statistical tests were two-sided
and a p value ≤0.05 was considered statistically
signiﬁcant.
Ethical Standards
Ethical approval for this study was obtained from The
Joint South London and Maudsley and The Institute of
Psychiatry NHS Research Ethics Committee. Ethical
approval was granted on 17 July 2009 (REC ref. no.
09/H080/41).
Results
The clinical characteristics of the study population are
shown in Table 2. Mean age was 43.6 years (S.D. = 10.1)
and mean duration of illness was 15.7 years (S.D. =
10.3); 57% (n = 257) were male. In respect of ethnicity,
55% (n = 239) were of Caucasian ethnicity, while 33%
(n = 143) were of black African or black Caribbean eth-
nicity, with 7% (n = 27) of Asian ethnicity and 5% (n =
22) of mixed ethnicity.
Only 6% (n = 25) of the study population were not
treated with antipsychotic medication. Of the partici-
pants, 30% (n = 127) were prescribed clozapine and
16% (n = 70) olanzapine. Of the participants, 75%
(n = 321) were treated with second-generation (atypi-
cal) antipsychotics (including clozapine and olanza-
pine), 16% (n = 71) were treated with ﬁrst-generation
antipsychotics and 8% (n = 36) were treated with a
combination of antipsychotics.
Cardiovascular risk factors (see Table 3)
Of the subjects, 48% (192/398) were obese (BMI > 30 kg/
m2). Female patients had signiﬁcantly higher BMIs
than males [t = 2.329, degrees of freedom (df) = 426,
p < 0.020].
In all, 83% had abdominal obesity, with 95% (160/
169) of females meeting the IDF criterion for
central obesity, signiﬁcantly higher than males (74%,
n = 167/227) (χ2 = 29.994, p < 0.0001). Of the participants,
89% (305/342) had evidence of dyslipidaemia, deﬁned
as the presence of at least one abnormal lipid par-
ameter (high total cholesterol, low high-density
lipoprotein-cholesterol, high triglyceride) (n = 233) or
treatment with lipid-lowering drugs (n = 72). Sixty-six
Table 2. Clinical characteristics of the study population (n = 450)
Total Males (n = 257) Females (n = 193)
Mean age, years (S.D.) (n = 449) 43.6 (10.1) 42.7 (9.9) 44.8 (10.2)
Mean duration of illness, years (S.D.) (n = 358) 15.7 (10.3) 16.5 (10.3) 14.7 (10.3)
Mean PANSS total score (S.D.) (n = 417) 51.2 (14.1) 51.5 (14.3) 50.9 (13.9)
Mean PANSS positive symptom scale score (S.D.) (n = 421) 11.8 (5.0) 12.0 (5.1) 11.5 (4.8)
Mean PANSS negative symptom scale score (S.D.) (n = 418) 12.9 (4.9) 13.1 (4.9) 12.6 (5.0)
Mean MADRS score (S.D.) (n = 427) 11.0 (9.5) 10.6 (9.6) 11.6 (9.2)
Mean GAF score (S.D.) (n = 425) 59.2 (13.1) 59.0 (13.6) 59.9 (12.5)
Diagnosis, n (%) (n = 423; 245 males, 178 females)
Schizophrenia 299 (71) 191 108
Schizo-affective disorder 56 (13) 19 37
Bipolar affective disorder 52 (12) 28 24
Depression 11 (3) 5 6
Delusional disorder 5 (1) 2 3
S.D., Standard deviation; PANSS, Positive And Negative Syndrome Scale; MADRS, Montgomery–Åsberg Depression Rating
Scale; GAF, Global Assessment of Functioning.
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people out of the 330 (20%) for whom we had data re-
garding either previous diagnosis of diabetes mellitus
(n = 38) and/or had relevant blood results (n = 28) met
the criteria for type 2 diabetes mellitus. An additional
85/286 (30%) had evidence of glucose dysregulation
on their blood tests. Hypertension was present in
214/398 (54%), of whom 62 were on anti-hypertensive
therapy. Nearly half (49%, n = 195/398) were hyperten-
sive on measurement. Of the subjects, 62% (268/432)
smoked tobacco, smoking an average of 18.2 (S.D. =
11.6) cigarettes per day.
There was no signiﬁcant difference between mean
BMI (p = 0.241) and waist circumference (p = 0.437)
when stratiﬁed by geographical location (by borough).
The prescription of either olanzapine or clozapine
(n = 191) (which are the antipsychotic medications tra-
ditionally associated with the highest risk of metabolic
dysfunction) was not associated with an increased
rate of obesity (n = 80, 42%) compared with those
not prescribed either dibenzodiazepine (n = 113, 54%)
(χ2 = 1.270, df = 1, p = 0.153). When clozapine alone
(n = 117) was compared with other antipsychotics (ex-
cluding olanzapine), no excess in obesity was found
on clozapine (47%, n = 55) versus other antipsychotics
(52%, n = 99) (χ2 = 0.675, p = 0.241). Also, there was no
excess of other cardiometabolic risk factors [dyslipi-
daemia (p = 0.418), hypertension (p = 0.546) and dia-
betes (p = 0.463)].
Ethnicity
Those of white ethnicity had larger mean waist circum-
ferences (mean = 108.5 cm, S.D. = 17.0) than those of
black African or Caribbean ethnicity (mean = 104.4
cm, S.D. = 16.9) (t = 2.225, df = 345, p = 0.027). White
patients had higher serum triglycerides than black
African or Caribbean patients (mean difference = 0.89,
p < 0.003). However, there were no signiﬁcant differ-
ences in overall rates of dyslipidaemia (p = 0.545), hy-
pertension (p = 0.101), diabetes (p = 0.298) and obesity
(BMI > 30 kg/m2) (p = 0.140). By gender, females of
black African or Caribbean ethnicity had signiﬁcantly
higher rates of obesity (n = 28/37) as measured by
BMI than females of white ethnicity (n = 35/63) (χ2 =
4.048, p = 0.035).
MetS
Of the 450 participants, there were 308 patients with
complete laboratory and clinical measures to allow
MetS status to be conﬁrmed. In this group, the preva-
lence of IDF MetS was 56.8% (n = 175/308). The preva-
lence of the MetS as deﬁned by the ATP-III criteria was
56.2% (n = 173/308). Those with IDF MetS were older
(mean age = 44.68 years, S.D. = 9.8) than those without
IDF MetS (42.12 years, S.D. = 10.4) (t =−2.28, p = 0.028).Ta
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There was no difference in duration of illness (p = 0.358),
or the use of clozapine (p = 0.282) or olanzapine
(p = 0.303) in those with IDF MetS compared with
those without. White patients had higher rates of IDF
MetS (n = 114/171) than those of black African or
Caribbean ethnicity (n = 47/101) (χ2 = 10.654, p = 0.001),
with this most pronounced in white males who
had signiﬁcantly higher rates of IDF MetS (n = 66/96)
than males of black African or Caribbean heritage
(n = 29/63) (χ2 = 8.143, p = 0.004).
Of the 13 individuals who were not prescribed anti-
psychotics and who had complete measures to allow
for MetS status to be conﬁrmed, eight met the criteria
for IDF MetS.
Psychopathology and cardiometabolic risk factors
(see Table 4)
A consistent relationship was found between cardiome-
tabolic risk factors and functional impairment as mea-
sured by GAF scores. Degree of psychosis as
measured by the PANSS and subscale scores was not
signiﬁcantly associated with any individual cardiometa-
bolic risk factor. The only individual cardiometabolic
risk factor associated with depressive symptomatology
(MADRS) was obesity (p = 0.032)
There was no relationship between duration of
psychotic illness and any of obesity (BMI > 30 kg/m2)
(t = 0.410, df = 329, p = 0.682), hypertension (t =−1.346,
p = 0.179), dyslipidaemia (t =−0.144, p = 0.886) or pres-
ence of diabetes mellitus (t =−0.992, df = 251, p = 0.322).
Drug and alcohol use
Of the respondents, 28% (n = 68/291) had hazardous/
harmful alcohol use (AUDIT score≥ 8), while the al-
cohol intake of a further 4% (n = 12/291) indicated the
need for diagnostic evaluation for alcohol dependence
syndrome (AUDIT score≥ 20).
Of the respondents, 18% (n = 76/422) were current
cannabis users, with 52 people identiﬁed through the
Timeline Follow-Back procedure and a further 24 iden-
tiﬁed through a cannabinoid-positive urinary drug
screen.
Other substance use
Of the participants, 3% (n = 13/439) were cocaine or
amphetamine users, 1.4% (n = 6) reported ongoing
crack cocaine use and less than 1% (n = 3) reported
using ecstasy.
Lifestyle measures
Of the participants, 23% (102/435) had a high saturated
fat intake score on the DINE, 29.7% (129/435) had a
medium fat intake, while 47% (204/435) had a low
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saturated fat intake; 51% of the participants (n = 210)
had a low ﬁbre intake, with only 25% (n = 102) report-
ing a high ﬁbre intake.
Of the participants, 44% (n = 196) were engaging
in low-intensity physical activity, 44% (n = 200) engaged
in moderate-intensity physical activity, while 12%
(n = 54) participated in high-intensity physical activity.
Engaging in high levels of physical activity was
associated with lower rates of obesity (χ2 = 20.944,
p < 0.0001) and dyslipidaemia (χ2 = 17.537, p = 0.001)
compared with low-intensity physical activity. Further,
lower rates of the MetS were found in those with
high-intensity physical activity (n = 15/41), compared
with those engaging in low-intensity physical activity
(n = 160/267) (χ2 = 7.891, p = 0.004).
Discussion
This cohort of individuals with established psychosis
had a high prevalence of both individual cardiometa-
bolic risk factors and of the MetS. Rates of central obes-
ity were alarmingly high at 83%, with almost all
women (95%) exceeding the IDF threshold. Half the
sample were obese, half had hypertriglyceridaemia
and 54% were hypertensive. Of the study population,
50% had evidence of glucose dysregulation, including
20% of the sample with type 2 diabetes, which is
much higher than the rate in the general UK population
(International Diabetes Federation, 2013). This excess is
ampliﬁed when an aged-matched comparison is used;
the expected prevalence of diabetes in UK residents
with an age range from 35 to 54 years would be 9.4%
for men and 6.6% for women (Craig & Mindell, 2011).
Of our participants, 56.8% met criteria for the MetS,
greatly exceeding the international ﬁgure of 34% de-
scribed in a recent meta-analysis of the MetS in schizo-
phrenia (Mitchell et al. 2013). This meta-analysis found
a lack of homogeneity in the distribution of MetS
prevalence across individual studies. Similar rates of
cardiometabolic risk to what we found have been iden-
tiﬁed in a large Australian prevalence survey in psy-
chosis, where rates of abdominal obesity greater than
80% were found, as well as comparable rates of the
MetS, dyslipidaemia and hypertension (Galletly et al.
2012). Our prevalence rates thus place this UK popu-
lation at the higher end globally for cardiometabolic
risk factors in psychosis. Given that UK general popu-
lation studies have identiﬁed rates of the MetS of 25–
34%, the almost doubled rate in psychosis is striking
(Khunti et al. 2010; Langan et al. 2012) and behoves
us to investigate the antecedents and remedies.
Consistent with general population studies, but in con-
trast to some cross-sectional studies in psychosis, we
found no gender difference in the rates of the MetS
(Ford, 2005), although we did ﬁnd higher rates of
obesity (as deﬁned by BMI) in females (61% v. 42%)
(McEvoy et al. 2005; Bobes et al. 2007). There were eth-
nic differences in rates of the MetS, with those of white
ethnicity showing higher rates compared with those of
black African or Caribbean ethnicity, in keeping with
previous work (McEvoy et al. 2005; Keenan et al.
2013), results which have not been consistently demon-
strated in the general population (Keenan et al. 2013).
Lifestyle choices amplify the potential consequences
of abnormal metabolic parameters in this population:
62% were smokers, hugely in excess of the current
smoking rates in the general UK population of 20%
(Health & Social Care Information Centre, 2013). A re-
cent 11-year follow-up of 517 people with schizophrenia
showed an overall standardized mortality ratio of 2.80,
smoking being a very strong predictor of death (relative
risk of 4.66) (Dickerson et al. 2014). Smoking not only
increases the risk of early death, but also complicates
treatment, in that the hydrocarbons in cigarette smoke
accelerate the metabolism of dibenzodiazepines, cloza-
pine and olanzapine (Rostami-Hodjegan et al. 2004).
Until recently, clinicians have shown little interest in
supporting smoking cessation in psychosis patients.
However, ﬁndings from a systematic review have dem-
onstrated that people with schizophrenia want to stop
smoking and that it is possible to help them to do so
(Banham & Gilbody, 2010) and it is logical that this
should now be a priority public health measure.
Lack of exercise was common among the study
population, with only 12% of individuals participating
in high-intensity physical activity, consistent with pre-
vious reports (Faulkner et al. 2006), with high-intensity
physical activity associated with lower rates of obesity
and dyslipidaemia. As exercise is linked to greater lon-
gevity in the general population (Paffenbarger et al.
1993; Manson et al. 2002), it is likely that greater empha-
sis on engaging in physical activity among those with
severe mental illnesses (SMI) would help reduce mor-
tality risk (Vancampfort et al. 2010). This will require
addressing the individual barriers to regular physical
activity and promoting it within the structure of com-
munity treatment programmes (Vancampfort et al.
2012) but will also entail addressing wider organiza-
tional barriers to regular physical activity and other
health promotion programmes (O’Brien et al. 2014).
We did not identify any associations between indivi-
duals’ psychopathology scores on PANSS and their car-
diometabolic risk. However, we did ﬁnd associations
between increased functional impairment and obesity,
diabetes and hypertension and between higher de-
pression scores and obesity. Of note, in the US Clinical
Antipsychotic Trials of Intervention Effectiveness
(CATIE) study, the PANSS mean total score of 75.9
was higher than in IMPaCT (51.2) – with lower NCEP
ATP-III MetS rates of 36% in CATIE compared with
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the ATP-III MetS rate of 56% in IMPaCT, meaning that
our higher rates of cardiometabolic risk are not a result
of illness severity (Meyer et al. 2005).
The rate of the MetS in the BPAD subgroup was
66%, which is higher than previously reported rates
of 22–30% (Garcia-Portilla et al. 2008; van Winkel
et al. 2008). This may relate more to service bias than
diagnostic factors. Patients with bipolar disorder re-
quiring ongoing secondary care management in the
UK may have a greater clinical need than those mana-
ged in primary care and as we have demonstrated an
effect of global function on cardiometabolic risk, this
is one potential explanation, although the numbers
were too small to test this hypothesis.
Despite the mean duration of illness being 15.7
years, we found no effect of duration of illness on the
prevalence of the MetS, in contrast to the meta-analysis
conducted by Mitchell et al. (2013). Even though our
study excluded, for pragmatic reasons, those people
registered with early intervention services, which man-
age younger people for up to 3 years from ﬁrst presen-
tation, we would have expected to ﬁnd an effect.
A high proportion of this sample was prescribed
dibenzodiazepines, which are associated with early
emergence of cardiometabolic risk factors (Howes
et al. 2004; Nielsen et al. 2010). However, we found
no differences in cardiac risk factors between those
on clozapine or olanzapine and those not. One poten-
tial explanation is that the cardiometabolic effect pla-
teaus and becomes more evenly distributed over a
more prolonged course of illness. However, as we do
not have access to treatment histories, it may also be
that this homogeneity across medications reﬂects the
cumulative effects of medication changes over the
years. This lack of difference is especially interesting
in light of the evidence that patients with schizo-
phrenia treated with clozapine have the least reduction
in life expectancy of all patients with schizophrenia
(Tiihonen et al. 2009; Hayes et al. 2014).
Strengths of this study include a sample of randomly
selected individuals with psychosis from diverse eth-
nic backgrounds and the mix of urban and rural loca-
tions adding to the generalizability of the study
ﬁndings. Limitations of the study include the cross-
sectional design, and the lack of a control group. We
have not adjusted for the effect of socio-economic
deprivation. The sample was recruited from across
England, but predominantly from Greater London, in-
cluding some boroughs with high levels of depri-
vation, though we identiﬁed no difference in
metabolic variables by borough. A recent Scottish
paper noted an excess of mortality in SMI linked to
deprivation, although this effect was not evident for
deaths due to cerebrovascular disease or CVD
(Langan Martin et al. 2014). The missing data from
metabolic measures and clinical assessment scales
may have introduced a selection bias into the study,
but it is not obvious what effect such a bias would re-
sult in. Measures such as duration of illness were self-
reported and thus are non-validated. We have no data
on duration of antipsychotic treatment and previous
antipsychotic treatments used over the longitudinal
course of an individual’s illness, both of which are con-
founding factors that could potentially make an impact
on an individual’s cardiometabolic risk factors. The ex-
clusion of FEP patients from this study recognizes the
different CVD proﬁles in the early stages of psychosis.
Data on the evolution of CVD risk factors from ﬁrst
presentation are being gathered as part of a different
project within IMPaCT. To have included FEP data
within this study would have underestimated the ex-
tent of the problem which patients with established
psychosis, their carers and their clinicians face.
Because of the design of the study, individuals with
established psychosis cared for by their general practi-
tioners were not included in the study population. This
group is estimated to make up 30% of all patients with
SMI in the UK (Reilly et al. 2012). Our study popu-
lation, compared with this primary care-only popu-
lation, may be functionally or symptomatically more
impaired; and antipsychotic prescribing patterns may
be different – for instance, clozapine is rarely pre-
scribed in primary care. Thus the study’s ﬁndings
may not necessarily generalize to those patients living
in the community who share these same diagnoses but
who are not managed in secondary care.
Conclusion
The results from this study are alarming and draw atten-
tion to the huge rates of modiﬁable cardiometabolic risk
factors in people with established psychosis in the UK.
The prevalence of the MetS in people with established
psychosis in this UK sample is 56.8%. The main deﬁning
measure of the MetS, waist circumference, exceeded the
IDF diagnostic cut-off in 83% of our patients, and in
95% of female patients. Although central obesity is
known tobe thebest predictorofmorbidityandmortality
(Zimmet et al. 2001), waist circumference has not to date
been routinely measured in people with psychosis,
although it has now been included in the latest National
Institute of Health and Clinical Excellence (2014) guide-
lines for schizophrenia. Practice in in-patient psychiatric
services has improvedwith the advent of incentivization
and of shared guidelines for CVD risk management in
psychosis such as the Lester Cardiometabolic Health
Resource (Lester et al. 2014). However, serious shortcom-
ings remain in themanagement of physical health care in
community-based patients, as evidenced by theNational
Audit of Schizophrenia ﬁndings (NAS, 2012; Crawford
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et al. 2014). Nevertheless, more tailoredwork is needed if
we wish to improve life expectancy in psychosis, with
theseﬁndings reinforcing theneed for routinemonitoring
of waist circumference in psychosis and assertive man-
agement of cardiovascular risk in peoplewith psychosis.
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